Description
Shortened spadin analog; TREK-1 blocker studied as an antidepressant
PE-22-28 is a synthetic neuropeptide under investigation for its potential to support brain function and protect neural integrity. Believed to influence key neural pathways that promote neuron survival and signaling efficiency. May help reduce oxidative stress and neuroinflammation – two major contributors to cognitive decline. May also play a role in mood regulation by modulating neurotransmitter activity.
- Djillani A, et al. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643. PMID: 28955242 | DOI: 10.3389/fphar.2017.00643
- Djillani A, et al. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacol Ther. 2019;194:185-198. PMID: 30291907 | DOI: 10.1016/j.pharmthera.2018.10.003
- Moha Ou Maati H, et al. Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology. 2012;62(1):278-288. PMID: 21807005 | DOI: 10.1016/j.neuropharm.2011.07.019
Note: One primary paper characterizes PE-22-28 itself; the others are foundational spadin references from the same laboratory.
